nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Rash papular—Vemurafenib—melanoma	0.029	0.0466	CcSEcCtD
Brimonidine—Pain of skin—Bleomycin—melanoma	0.0278	0.0447	CcSEcCtD
Brimonidine—Conjunctival oedema—Carmustine—melanoma	0.0206	0.0331	CcSEcCtD
Brimonidine—Hyperaemia—Carmustine—melanoma	0.0189	0.0304	CcSEcCtD
Brimonidine—Burning sensation—Carmustine—melanoma	0.00823	0.0132	CcSEcCtD
Brimonidine—Arthritis—Vemurafenib—melanoma	0.00808	0.013	CcSEcCtD
Brimonidine—Scotoma—Carmustine—melanoma	0.00753	0.0121	CcSEcCtD
Brimonidine—Scotoma—Temozolomide—melanoma	0.00728	0.0117	CcSEcCtD
Brimonidine—Dry skin—Vemurafenib—melanoma	0.00719	0.0116	CcSEcCtD
Brimonidine—Lacrimation—Docetaxel—melanoma	0.00625	0.01	CcSEcCtD
Brimonidine—Respiratory failure—Temozolomide—melanoma	0.00563	0.00904	CcSEcCtD
Brimonidine—Burning sensation—Docetaxel—melanoma	0.00529	0.0085	CcSEcCtD
Brimonidine—Coma—Carmustine—melanoma	0.00523	0.00839	CcSEcCtD
Brimonidine—Dry eye—Temozolomide—melanoma	0.0051	0.0082	CcSEcCtD
Brimonidine—Eye disorder—Vemurafenib—melanoma	0.00507	0.00815	CcSEcCtD
Brimonidine—Cardiac disorder—Vemurafenib—melanoma	0.00504	0.0081	CcSEcCtD
Brimonidine—Abnormal vision—Carmustine—melanoma	0.00499	0.00801	CcSEcCtD
Brimonidine—Angiopathy—Vemurafenib—melanoma	0.00493	0.00791	CcSEcCtD
Brimonidine—Mediastinal disorder—Vemurafenib—melanoma	0.00489	0.00786	CcSEcCtD
Brimonidine—Arthritis—Bleomycin—melanoma	0.00489	0.00786	CcSEcCtD
Brimonidine—Scotoma—Docetaxel—melanoma	0.00484	0.00777	CcSEcCtD
Brimonidine—Abnormal vision—Temozolomide—melanoma	0.00482	0.00774	CcSEcCtD
Brimonidine—Diabetes mellitus—Carmustine—melanoma	0.00477	0.00767	CcSEcCtD
Brimonidine—Erythema—Vemurafenib—melanoma	0.00473	0.00759	CcSEcCtD
Brimonidine—Swelling—Carmustine—melanoma	0.00471	0.00756	CcSEcCtD
Brimonidine—Dysgeusia—Vemurafenib—melanoma	0.00463	0.00744	CcSEcCtD
Brimonidine—Eye pain—Carmustine—melanoma	0.0046	0.00739	CcSEcCtD
Brimonidine—Lethargy—Dactinomycin—melanoma	0.00453	0.00727	CcSEcCtD
Brimonidine—Eye pain—Temozolomide—melanoma	0.00444	0.00714	CcSEcCtD
Brimonidine—Nasal congestion—Temozolomide—melanoma	0.0044	0.00707	CcSEcCtD
Brimonidine—Eye irritation—Docetaxel—melanoma	0.0043	0.00691	CcSEcCtD
Brimonidine—Cough—Vemurafenib—melanoma	0.00412	0.00663	CcSEcCtD
Brimonidine—Arthralgia—Vemurafenib—melanoma	0.00402	0.00646	CcSEcCtD
Brimonidine—Myalgia—Vemurafenib—melanoma	0.00402	0.00646	CcSEcCtD
Brimonidine—Face oedema—Carmustine—melanoma	0.00401	0.00644	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.004	0.00642	CcSEcCtD
Brimonidine—Lacrimation increased—Docetaxel—melanoma	0.00399	0.00641	CcSEcCtD
Brimonidine—Face oedema—Temozolomide—melanoma	0.00387	0.00622	CcSEcCtD
Brimonidine—Infection—Vemurafenib—melanoma	0.00383	0.00616	CcSEcCtD
Brimonidine—Nervous system disorder—Vemurafenib—melanoma	0.00378	0.00608	CcSEcCtD
Brimonidine—Skin disorder—Vemurafenib—melanoma	0.00375	0.00602	CcSEcCtD
Brimonidine—Respiratory failure—Docetaxel—melanoma	0.00374	0.00601	CcSEcCtD
Brimonidine—Dry skin—Temozolomide—melanoma	0.00368	0.00591	CcSEcCtD
Brimonidine—Hypotension—Vemurafenib—melanoma	0.0036	0.00579	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00351	0.00565	CcSEcCtD
Brimonidine—Bronchitis—Temozolomide—melanoma	0.00333	0.00536	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00333	0.00535	CcSEcCtD
Brimonidine—Fatigue—Vemurafenib—melanoma	0.00333	0.00534	CcSEcCtD
Brimonidine—Depression—Carmustine—melanoma	0.00319	0.00512	CcSEcCtD
Brimonidine—Depression—Temozolomide—melanoma	0.00308	0.00495	CcSEcCtD
Brimonidine—Flushing—Bleomycin—melanoma	0.00305	0.0049	CcSEcCtD
Brimonidine—Pharyngitis—Dactinomycin—melanoma	0.00305	0.00489	CcSEcCtD
Brimonidine—Swelling—Docetaxel—melanoma	0.00302	0.00486	CcSEcCtD
Brimonidine—Sinusitis—Temozolomide—melanoma	0.0029	0.00466	CcSEcCtD
Brimonidine—Erythema—Bleomycin—melanoma	0.00286	0.0046	CcSEcCtD
Brimonidine—Flushing—Dactinomycin—melanoma	0.00285	0.00457	CcSEcCtD
Brimonidine—Hypersensitivity—Vemurafenib—melanoma	0.00284	0.00457	CcSEcCtD
Brimonidine—Visual disturbance—Docetaxel—melanoma	0.00281	0.00452	CcSEcCtD
Brimonidine—Asthenia—Vemurafenib—melanoma	0.00277	0.00445	CcSEcCtD
Brimonidine—Visual impairment—Carmustine—melanoma	0.00277	0.00445	CcSEcCtD
Brimonidine—Pharyngitis—Temozolomide—melanoma	0.00275	0.00442	CcSEcCtD
Brimonidine—Pruritus—Vemurafenib—melanoma	0.00273	0.00438	CcSEcCtD
Brimonidine—Lethargy—Docetaxel—melanoma	0.00272	0.00437	CcSEcCtD
Brimonidine—Eye disorder—Carmustine—melanoma	0.00268	0.00431	CcSEcCtD
Brimonidine—Visual impairment—Temozolomide—melanoma	0.00267	0.0043	CcSEcCtD
Brimonidine—Erythema—Dactinomycin—melanoma	0.00267	0.00429	CcSEcCtD
Brimonidine—Flushing—Carmustine—melanoma	0.00267	0.00428	CcSEcCtD
Brimonidine—Eye disorder—Temozolomide—melanoma	0.00259	0.00417	CcSEcCtD
Brimonidine—Cardiac disorder—Temozolomide—melanoma	0.00258	0.00414	CcSEcCtD
Brimonidine—Flushing—Temozolomide—melanoma	0.00258	0.00414	CcSEcCtD
Brimonidine—Arrhythmia—Carmustine—melanoma	0.00257	0.00412	CcSEcCtD
Brimonidine—Dizziness—Vemurafenib—melanoma	0.00255	0.0041	CcSEcCtD
Brimonidine—Angiopathy—Temozolomide—melanoma	0.00252	0.00404	CcSEcCtD
Brimonidine—Mental disorder—Carmustine—melanoma	0.00252	0.00404	CcSEcCtD
Brimonidine—Immune system disorder—Temozolomide—melanoma	0.00251	0.00403	CcSEcCtD
Brimonidine—Mediastinal disorder—Temozolomide—melanoma	0.0025	0.00402	CcSEcCtD
Brimonidine—Erythema—Carmustine—melanoma	0.0025	0.00402	CcSEcCtD
Brimonidine—Cough—Bleomycin—melanoma	0.0025	0.00401	CcSEcCtD
Brimonidine—Dry skin—Docetaxel—melanoma	0.00245	0.00393	CcSEcCtD
Brimonidine—Chest pain—Bleomycin—melanoma	0.00244	0.00392	CcSEcCtD
Brimonidine—Myalgia—Bleomycin—melanoma	0.00244	0.00392	CcSEcCtD
Brimonidine—Rash—Vemurafenib—melanoma	0.00243	0.00391	CcSEcCtD
Brimonidine—Mental disorder—Temozolomide—melanoma	0.00243	0.00391	CcSEcCtD
Brimonidine—Dermatitis—Vemurafenib—melanoma	0.00243	0.0039	CcSEcCtD
Brimonidine—Headache—Vemurafenib—melanoma	0.00242	0.00388	CcSEcCtD
Brimonidine—Erythema—Temozolomide—melanoma	0.00242	0.00388	CcSEcCtD
Brimonidine—Discomfort—Bleomycin—melanoma	0.00241	0.00387	CcSEcCtD
Brimonidine—Nasopharyngitis—Docetaxel—melanoma	0.00239	0.00383	CcSEcCtD
Brimonidine—Dysgeusia—Temozolomide—melanoma	0.00237	0.0038	CcSEcCtD
Brimonidine—Vision blurred—Carmustine—melanoma	0.00236	0.00378	CcSEcCtD
Brimonidine—Oedema—Bleomycin—melanoma	0.00234	0.00375	CcSEcCtD
Brimonidine—Infection—Bleomycin—melanoma	0.00232	0.00373	CcSEcCtD
Brimonidine—Nausea—Vemurafenib—melanoma	0.00229	0.00368	CcSEcCtD
Brimonidine—Vision blurred—Temozolomide—melanoma	0.00228	0.00366	CcSEcCtD
Brimonidine—Myalgia—Dactinomycin—melanoma	0.00227	0.00365	CcSEcCtD
Brimonidine—Discomfort—Dactinomycin—melanoma	0.00225	0.00361	CcSEcCtD
Brimonidine—Hypotension—Bleomycin—melanoma	0.00218	0.00351	CcSEcCtD
Brimonidine—Oedema—Dactinomycin—melanoma	0.00218	0.0035	CcSEcCtD
Brimonidine—Infection—Dactinomycin—melanoma	0.00217	0.00348	CcSEcCtD
Brimonidine—Hypertension—Carmustine—melanoma	0.00216	0.00347	CcSEcCtD
Brimonidine—Palpitations—Temozolomide—melanoma	0.00213	0.00343	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Bleomycin—melanoma	0.00213	0.00342	CcSEcCtD
Brimonidine—Chest pain—Carmustine—melanoma	0.00213	0.00342	CcSEcCtD
Brimonidine—Myalgia—Carmustine—melanoma	0.00213	0.00342	CcSEcCtD
Brimonidine—Anxiety—Carmustine—melanoma	0.00212	0.00341	CcSEcCtD
Brimonidine—Cough—Temozolomide—melanoma	0.00211	0.00339	CcSEcCtD
Brimonidine—Paraesthesia—Bleomycin—melanoma	0.0021	0.00337	CcSEcCtD
Brimonidine—Hypertension—Temozolomide—melanoma	0.00209	0.00335	CcSEcCtD
Brimonidine—Dyspnoea—Bleomycin—melanoma	0.00208	0.00335	CcSEcCtD
Brimonidine—Myalgia—Temozolomide—melanoma	0.00206	0.0033	CcSEcCtD
Brimonidine—Arthralgia—Temozolomide—melanoma	0.00206	0.0033	CcSEcCtD
Brimonidine—Anxiety—Temozolomide—melanoma	0.00205	0.00329	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00204	0.00328	CcSEcCtD
Brimonidine—Oedema—Carmustine—melanoma	0.00204	0.00328	CcSEcCtD
Brimonidine—Discomfort—Temozolomide—melanoma	0.00203	0.00326	CcSEcCtD
Brimonidine—Infection—Carmustine—melanoma	0.00203	0.00326	CcSEcCtD
Brimonidine—Dry mouth—Temozolomide—melanoma	0.00201	0.00323	CcSEcCtD
Brimonidine—Pain—Bleomycin—melanoma	0.002	0.00321	CcSEcCtD
Brimonidine—Conjunctivitis—Docetaxel—melanoma	0.002	0.00321	CcSEcCtD
Brimonidine—Tachycardia—Carmustine—melanoma	0.00199	0.0032	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00199	0.00319	CcSEcCtD
Brimonidine—Oedema—Temozolomide—melanoma	0.00197	0.00317	CcSEcCtD
Brimonidine—Infection—Temozolomide—melanoma	0.00196	0.00315	CcSEcCtD
Brimonidine—Nervous system disorder—Temozolomide—melanoma	0.00193	0.00311	CcSEcCtD
Brimonidine—Skin disorder—Temozolomide—melanoma	0.00192	0.00308	CcSEcCtD
Brimonidine—Hypotension—Carmustine—melanoma	0.00191	0.00306	CcSEcCtD
Brimonidine—Fatigue—Dactinomycin—melanoma	0.00188	0.00302	CcSEcCtD
Brimonidine—Pain—Dactinomycin—melanoma	0.00186	0.00299	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Carmustine—melanoma	0.00186	0.00299	CcSEcCtD
Brimonidine—Rhinitis—Docetaxel—melanoma	0.00185	0.00297	CcSEcCtD
Brimonidine—Insomnia—Carmustine—melanoma	0.00185	0.00296	CcSEcCtD
Brimonidine—Paraesthesia—Carmustine—melanoma	0.00183	0.00294	CcSEcCtD
Brimonidine—Pharyngitis—Docetaxel—melanoma	0.00183	0.00294	CcSEcCtD
Brimonidine—Dyspnoea—Carmustine—melanoma	0.00182	0.00292	CcSEcCtD
Brimonidine—Somnolence—Carmustine—melanoma	0.00181	0.00291	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Temozolomide—melanoma	0.0018	0.00289	CcSEcCtD
Brimonidine—Insomnia—Temozolomide—melanoma	0.00178	0.00286	CcSEcCtD
Brimonidine—Visual impairment—Docetaxel—melanoma	0.00178	0.00286	CcSEcCtD
Brimonidine—Paraesthesia—Temozolomide—melanoma	0.00177	0.00284	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Carmustine—melanoma	0.00176	0.00283	CcSEcCtD
Brimonidine—Dyspnoea—Temozolomide—melanoma	0.00176	0.00282	CcSEcCtD
Brimonidine—Somnolence—Temozolomide—melanoma	0.00175	0.00282	CcSEcCtD
Brimonidine—Pain—Carmustine—melanoma	0.00174	0.0028	CcSEcCtD
Brimonidine—Dyspepsia—Temozolomide—melanoma	0.00174	0.00279	CcSEcCtD
Brimonidine—Eye disorder—Docetaxel—melanoma	0.00172	0.00277	CcSEcCtD
Brimonidine—Hypersensitivity—Bleomycin—melanoma	0.00172	0.00277	CcSEcCtD
Brimonidine—Cardiac disorder—Docetaxel—melanoma	0.00171	0.00275	CcSEcCtD
Brimonidine—Flushing—Docetaxel—melanoma	0.00171	0.00275	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Temozolomide—melanoma	0.0017	0.00273	CcSEcCtD
Brimonidine—Fatigue—Temozolomide—melanoma	0.0017	0.00273	CcSEcCtD
Brimonidine—Pain—Temozolomide—melanoma	0.00169	0.00271	CcSEcCtD
Brimonidine—Asthenia—Bleomycin—melanoma	0.00168	0.00269	CcSEcCtD
Brimonidine—Angiopathy—Docetaxel—melanoma	0.00167	0.00269	CcSEcCtD
Brimonidine—Immune system disorder—Docetaxel—melanoma	0.00167	0.00268	CcSEcCtD
Brimonidine—Mediastinal disorder—Docetaxel—melanoma	0.00166	0.00267	CcSEcCtD
Brimonidine—Pruritus—Bleomycin—melanoma	0.00165	0.00266	CcSEcCtD
Brimonidine—Arrhythmia—Docetaxel—melanoma	0.00165	0.00265	CcSEcCtD
Brimonidine—Mental disorder—Docetaxel—melanoma	0.00162	0.0026	CcSEcCtD
Brimonidine—Erythema—Docetaxel—melanoma	0.00161	0.00258	CcSEcCtD
Brimonidine—Hypersensitivity—Dactinomycin—melanoma	0.00161	0.00258	CcSEcCtD
Brimonidine—Dysgeusia—Docetaxel—melanoma	0.00157	0.00253	CcSEcCtD
Brimonidine—Asthenia—Dactinomycin—melanoma	0.00156	0.00251	CcSEcCtD
Brimonidine—Hypersensitivity—Carmustine—melanoma	0.0015	0.00241	CcSEcCtD
Brimonidine—Rash—Bleomycin—melanoma	0.00147	0.00237	CcSEcCtD
Brimonidine—Dermatitis—Bleomycin—melanoma	0.00147	0.00237	CcSEcCtD
Brimonidine—Asthenia—Carmustine—melanoma	0.00146	0.00235	CcSEcCtD
Brimonidine—Hypersensitivity—Temozolomide—melanoma	0.00145	0.00233	CcSEcCtD
Brimonidine—Syncope—Docetaxel—melanoma	0.00144	0.00231	CcSEcCtD
Brimonidine—Palpitations—Docetaxel—melanoma	0.00142	0.00228	CcSEcCtD
Brimonidine—Asthenia—Temozolomide—melanoma	0.00141	0.00227	CcSEcCtD
Brimonidine—Loss of consciousness—Docetaxel—melanoma	0.00141	0.00227	CcSEcCtD
Brimonidine—Cough—Docetaxel—melanoma	0.0014	0.00225	CcSEcCtD
Brimonidine—Pruritus—Temozolomide—melanoma	0.00139	0.00224	CcSEcCtD
Brimonidine—Nausea—Bleomycin—melanoma	0.00139	0.00223	CcSEcCtD
Brimonidine—Hypertension—Docetaxel—melanoma	0.00139	0.00223	CcSEcCtD
Brimonidine—Rash—Dactinomycin—melanoma	0.00137	0.00221	CcSEcCtD
Brimonidine—Arthralgia—Docetaxel—melanoma	0.00137	0.0022	CcSEcCtD
Brimonidine—Chest pain—Docetaxel—melanoma	0.00137	0.0022	CcSEcCtD
Brimonidine—Myalgia—Docetaxel—melanoma	0.00137	0.0022	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00136	0.00218	CcSEcCtD
Brimonidine—Dizziness—Carmustine—melanoma	0.00135	0.00217	CcSEcCtD
Brimonidine—Dry mouth—Docetaxel—melanoma	0.00134	0.00215	CcSEcCtD
Brimonidine—Oedema—Docetaxel—melanoma	0.00131	0.00211	CcSEcCtD
Brimonidine—Dizziness—Temozolomide—melanoma	0.0013	0.00209	CcSEcCtD
Brimonidine—Infection—Docetaxel—melanoma	0.0013	0.00209	CcSEcCtD
Brimonidine—Nausea—Dactinomycin—melanoma	0.00129	0.00208	CcSEcCtD
Brimonidine—Shock—Docetaxel—melanoma	0.00129	0.00207	CcSEcCtD
Brimonidine—Rash—Carmustine—melanoma	0.00129	0.00207	CcSEcCtD
Brimonidine—Nervous system disorder—Docetaxel—melanoma	0.00129	0.00207	CcSEcCtD
Brimonidine—Dermatitis—Carmustine—melanoma	0.00129	0.00206	CcSEcCtD
Brimonidine—Tachycardia—Docetaxel—melanoma	0.00128	0.00206	CcSEcCtD
Brimonidine—Headache—Carmustine—melanoma	0.00128	0.00205	CcSEcCtD
Brimonidine—Skin disorder—Docetaxel—melanoma	0.00127	0.00205	CcSEcCtD
Brimonidine—Rash—Temozolomide—melanoma	0.00124	0.002	CcSEcCtD
Brimonidine—Dermatitis—Temozolomide—melanoma	0.00124	0.002	CcSEcCtD
Brimonidine—Headache—Temozolomide—melanoma	0.00124	0.00198	CcSEcCtD
Brimonidine—Hypotension—Docetaxel—melanoma	0.00123	0.00197	CcSEcCtD
Brimonidine—Nausea—Carmustine—melanoma	0.00121	0.00195	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Docetaxel—melanoma	0.00119	0.00192	CcSEcCtD
Brimonidine—Insomnia—Docetaxel—melanoma	0.00119	0.0019	CcSEcCtD
Brimonidine—Paraesthesia—Docetaxel—melanoma	0.00118	0.00189	CcSEcCtD
Brimonidine—Nausea—Temozolomide—melanoma	0.00117	0.00188	CcSEcCtD
Brimonidine—Dyspnoea—Docetaxel—melanoma	0.00117	0.00188	CcSEcCtD
Brimonidine—Somnolence—Docetaxel—melanoma	0.00117	0.00187	CcSEcCtD
Brimonidine—Dyspepsia—Docetaxel—melanoma	0.00115	0.00185	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Docetaxel—melanoma	0.00113	0.00182	CcSEcCtD
Brimonidine—Fatigue—Docetaxel—melanoma	0.00113	0.00182	CcSEcCtD
Brimonidine—Pain—Docetaxel—melanoma	0.00112	0.0018	CcSEcCtD
Brimonidine—Hypersensitivity—Docetaxel—melanoma	0.000966	0.00155	CcSEcCtD
Brimonidine—Asthenia—Docetaxel—melanoma	0.000941	0.00151	CcSEcCtD
Brimonidine—Pruritus—Docetaxel—melanoma	0.000928	0.00149	CcSEcCtD
Brimonidine—Dizziness—Docetaxel—melanoma	0.000867	0.00139	CcSEcCtD
Brimonidine—Rash—Docetaxel—melanoma	0.000827	0.00133	CcSEcCtD
Brimonidine—Dermatitis—Docetaxel—melanoma	0.000826	0.00133	CcSEcCtD
Brimonidine—Headache—Docetaxel—melanoma	0.000821	0.00132	CcSEcCtD
Brimonidine—Nausea—Docetaxel—melanoma	0.000779	0.00125	CcSEcCtD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2—melanoma	8.96e-05	0.000237	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—E2F1—melanoma	8.9e-05	0.000236	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CB—melanoma	8.85e-05	0.000235	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDGFRA—melanoma	8.8e-05	0.000233	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CA—melanoma	8.79e-05	0.000233	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CG—melanoma	8.77e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD86—melanoma	8.76e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL8—melanoma	8.75e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PRKCA—melanoma	8.72e-05	0.000231	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ITGB3—melanoma	8.72e-05	0.000231	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—HRAS—melanoma	8.7e-05	0.000231	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EDN1—melanoma	8.69e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—MAPK3—melanoma	8.64e-05	0.000229	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—melanoma	8.64e-05	0.000229	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ABCB1—melanoma	8.59e-05	0.000228	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SYK—melanoma	8.56e-05	0.000227	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SPP1—melanoma	8.55e-05	0.000226	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAP2K2—melanoma	8.52e-05	0.000226	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL8—melanoma	8.51e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—melanoma	8.5e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGF1—melanoma	8.49e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CSF2—melanoma	8.49e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CD—melanoma	8.49e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NGFR—melanoma	8.4e-05	0.000222	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT3—melanoma	8.4e-05	0.000222	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ITGAV—melanoma	8.4e-05	0.000222	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—melanoma	8.36e-05	0.000222	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—E2F1—melanoma	8.31e-05	0.00022	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—melanoma	8.27e-05	0.000219	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—MAPK1—melanoma	8.22e-05	0.000218	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRA—melanoma	8.22e-05	0.000218	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—melanoma	8.17e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PRKCA—melanoma	8.14e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ITGB3—melanoma	8.14e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—melanoma	8.13e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—melanoma	8.13e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TERT—melanoma	8.1e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RAC1—melanoma	8.08e-05	0.000214	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SPP1—melanoma	7.98e-05	0.000211	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—melanoma	7.97e-05	0.000211	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAP2K2—melanoma	7.96e-05	0.000211	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL8—melanoma	7.95e-05	0.000211	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PRKCA—melanoma	7.91e-05	0.000209	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ERCC2—melanoma	7.84e-05	0.000208	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SOCS1—melanoma	7.78e-05	0.000206	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—melanoma	7.77e-05	0.000206	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAP2K1—melanoma	7.76e-05	0.000206	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—S100B—melanoma	7.76e-05	0.000206	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—melanoma	7.75e-05	0.000205	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—melanoma	7.71e-05	0.000204	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—melanoma	7.68e-05	0.000204	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—melanoma	7.63e-05	0.000202	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—melanoma	7.6e-05	0.000201	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TERT—melanoma	7.57e-05	0.0002	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RAC1—melanoma	7.55e-05	0.0002	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB4—melanoma	7.42e-05	0.000197	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—melanoma	7.41e-05	0.000196	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—melanoma	7.4e-05	0.000196	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARG—melanoma	7.36e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN2B—melanoma	7.35e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—melanoma	7.24e-05	0.000192	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—melanoma	7.18e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—melanoma	7.14e-05	0.000189	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FN1—melanoma	7.13e-05	0.000189	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD86—melanoma	7.11e-05	0.000188	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL8—melanoma	7.11e-05	0.000188	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EDN1—melanoma	7.06e-05	0.000187	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH1—melanoma	6.98e-05	0.000185	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—melanoma	6.92e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—melanoma	6.9e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF1—melanoma	6.9e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CSF2—melanoma	6.9e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CD80—melanoma	6.84e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIT—melanoma	6.83e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—melanoma	6.83e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APC—melanoma	6.83e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—NRAS—melanoma	6.83e-05	0.000181	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—melanoma	6.79e-05	0.00018	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—E2F1—melanoma	6.75e-05	0.000179	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGF—melanoma	6.75e-05	0.000179	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—melanoma	6.72e-05	0.000178	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—melanoma	6.7e-05	0.000178	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRA—melanoma	6.68e-05	0.000177	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—melanoma	6.67e-05	0.000177	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FN1—melanoma	6.66e-05	0.000177	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—melanoma	6.62e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ITGB3—melanoma	6.61e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRKCA—melanoma	6.61e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—melanoma	6.6e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—MAPK3—melanoma	6.54e-05	0.000173	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH1—melanoma	6.52e-05	0.000173	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SPP1—melanoma	6.48e-05	0.000172	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAP2K2—melanoma	6.46e-05	0.000171	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL8—melanoma	6.46e-05	0.000171	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—BRAF—melanoma	6.42e-05	0.00017	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD80—melanoma	6.39e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APC—melanoma	6.38e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIT—melanoma	6.38e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—melanoma	6.38e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—NRAS—melanoma	6.38e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGF—melanoma	6.3e-05	0.000167	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—melanoma	6.25e-05	0.000166	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—MAPK1—melanoma	6.22e-05	0.000165	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—melanoma	6.22e-05	0.000165	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—melanoma	6.19e-05	0.000164	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—melanoma	6.17e-05	0.000163	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TERT—melanoma	6.15e-05	0.000163	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RAC1—melanoma	6.13e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MAPK3—melanoma	6.11e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAP2K1—melanoma	6.04e-05	0.00016	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—melanoma	6e-05	0.000159	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—BRAF—melanoma	5.99e-05	0.000159	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARG—melanoma	5.98e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—melanoma	5.94e-05	0.000157	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—melanoma	5.88e-05	0.000156	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—melanoma	5.88e-05	0.000156	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—melanoma	5.84e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—melanoma	5.84e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—melanoma	5.83e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—MAPK1—melanoma	5.81e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—melanoma	5.81e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—melanoma	5.79e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FGF2—melanoma	5.75e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAP2K1—melanoma	5.64e-05	0.000149	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—melanoma	5.62e-05	0.000149	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—melanoma	5.61e-05	0.000149	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—melanoma	5.55e-05	0.000147	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—melanoma	5.49e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—melanoma	5.45e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FN1—melanoma	5.41e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—melanoma	5.4e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—melanoma	5.38e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—melanoma	5.38e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FGF2—melanoma	5.37e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—melanoma	5.3e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH1—melanoma	5.3e-05	0.00014	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—melanoma	5.23e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD80—melanoma	5.19e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—melanoma	5.18e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APC—melanoma	5.18e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIT—melanoma	5.18e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NRAS—melanoma	5.18e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGF—melanoma	5.12e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTEN—melanoma	5.05e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—melanoma	5.04e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL8—melanoma	5.03e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—melanoma	5.02e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—melanoma	4.99e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAPK3—melanoma	4.96e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—melanoma	4.95e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1B—melanoma	4.91e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—melanoma	4.89e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—BRAF—melanoma	4.87e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—melanoma	4.86e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—melanoma	4.81e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—melanoma	4.8e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—melanoma	4.78e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—melanoma	4.75e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—melanoma	4.74e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—MAPK1—melanoma	4.72e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—melanoma	4.72e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—melanoma	4.7e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL8—melanoma	4.7e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—melanoma	4.68e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—melanoma	4.66e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNB1—melanoma	4.64e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1B—melanoma	4.59e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAP2K1—melanoma	4.58e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—melanoma	4.55e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—melanoma	4.55e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—melanoma	4.54e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN1A—melanoma	4.53e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTEN—melanoma	4.52e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	4.51e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NFKB1—melanoma	4.5e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—melanoma	4.49e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—melanoma	4.49e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—melanoma	4.46e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—melanoma	4.46e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—melanoma	4.41e-05	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—melanoma	4.37e-05	0.000116	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FGF2—melanoma	4.36e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNB1—melanoma	4.33e-05	0.000115	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—melanoma	4.25e-05	0.000113	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN1A—melanoma	4.23e-05	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTEN—melanoma	4.22e-05	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NFKB1—melanoma	4.2e-05	0.000111	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—melanoma	4.12e-05	0.000109	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTEN—melanoma	4.1e-05	0.000109	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	4.1e-05	0.000108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—melanoma	4.08e-05	0.000108	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—melanoma	4.08e-05	0.000108	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—melanoma	4.04e-05	0.000107	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRAS—melanoma	4.03e-05	0.000107	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—melanoma	4.02e-05	0.000107	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	3.97e-05	0.000105	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK3—melanoma	3.86e-05	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL8—melanoma	3.81e-05	0.000101	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—melanoma	3.81e-05	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.79e-05	0.0001	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—melanoma	3.78e-05	0.0001	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRAS—melanoma	3.77e-05	9.98e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—melanoma	3.76e-05	9.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.72e-05	9.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.68e-05	9.76e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.67e-05	9.73e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—melanoma	3.67e-05	9.73e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—melanoma	3.65e-05	9.67e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—melanoma	3.64e-05	9.66e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—melanoma	3.63e-05	9.61e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK3—melanoma	3.61e-05	9.56e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—melanoma	3.56e-05	9.44e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—melanoma	3.55e-05	9.41e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	3.52e-05	9.32e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—melanoma	3.51e-05	9.3e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—melanoma	3.47e-05	9.19e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—melanoma	3.45e-05	9.14e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	3.44e-05	9.11e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MAPK1—melanoma	3.43e-05	9.09e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—melanoma	3.43e-05	9.09e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTEN—melanoma	3.43e-05	9.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NFKB1—melanoma	3.41e-05	9.04e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—melanoma	3.35e-05	8.86e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—melanoma	3.24e-05	8.59e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	3.19e-05	8.45e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—melanoma	3.1e-05	8.21e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—melanoma	3.08e-05	8.17e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—melanoma	3.07e-05	8.13e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRAS—melanoma	3.06e-05	8.11e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	2.98e-05	7.89e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—melanoma	2.95e-05	7.82e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK3—melanoma	2.93e-05	7.76e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—melanoma	2.91e-05	7.71e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—melanoma	2.89e-05	7.66e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—melanoma	2.88e-05	7.63e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—melanoma	2.85e-05	7.55e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—melanoma	2.82e-05	7.48e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.79e-05	7.39e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—melanoma	2.79e-05	7.38e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—melanoma	2.76e-05	7.3e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—melanoma	2.64e-05	6.99e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—melanoma	2.63e-05	6.98e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—melanoma	2.6e-05	6.9e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—melanoma	2.43e-05	6.45e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	2.42e-05	6.41e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—melanoma	2.36e-05	6.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—melanoma	2.34e-05	6.2e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—melanoma	2.24e-05	5.93e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—melanoma	2.14e-05	5.68e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—melanoma	1.98e-05	5.24e-05	CbGpPWpGaD
